Taiho Oncology, Inc.
Clinical trials sponsored by Taiho Oncology, Inc., explained in plain language.
A subsidiary of Otsuka Holdings focused on oncology treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Cancer cocktail shows promise in early trial Results expected Oct 2026 (estimated)
- New study checks if kidney disease affects cancer drug safety Results expected Dec 2026 (estimated)
- New targeted drug shows promise for rare bile duct cancer Results expected Dec 2026 (estimated)
- New study seeks safer dosing of cancer drug for patients with liver issues Results expected Dec 2026 (estimated)
- Cancer drug futibatinib gets a safety check in Long-Term rollover study Results expected Apr 2027 (estimated)
-
New hope for older leukemia patients with gentler drug combo
Disease control OngoingThis study tests a new two-drug combination (ASTX727 and venetoclax) in adults with acute myeloid leukemia who are 75 or older, or have health issues that make standard strong chemotherapy too risky. The goal is to see if the drugs work well together and can control the leukemia.…
Phase 1/2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Cancer cocktail shows promise in early trial
Disease control OngoingThis study tests a new drug called futibatinib combined with standard immunotherapy and chemotherapy in people with advanced esophageal or pancreatic cancer. The goal is to see if the combination can shrink tumors and control the disease. About 53 adults who have not had prior tr…
Phase 2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill plus chemo aims to stop lung cancer comeback in patients with rare mutations
Disease control OngoingThis phase 3 trial tests whether adding the targeted drug zipalertinib to standard chemotherapy can delay or prevent lung cancer from returning in people with early-stage non-small cell lung cancer (stages IB to IIIA) who have uncommon EGFR mutations. After complete tumor removal…
Phase 3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug combo shows promise for rare lung cancer mutation
Disease control OngoingThis study tests whether adding the experimental drug zipalertinib to standard chemotherapy works better than chemotherapy alone for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). About 285 adults who have not had prio…
Phase 3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Blood cancer drug ASTX727 gets extended trial for ongoing patients
Disease control By invitation onlyThis study offers continued treatment with the drug ASTX727 to adults with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes who were already benefiting from it in earlier studies. The main goal is to monitor long-term safety. About 332 partici…
Phase 2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Cancer drug futibatinib gets a safety check in Long-Term rollover study
Disease control OngoingThis study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…
Phase 2/3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New cancer drug ASTX660 tested in patients with no other options
Disease control OngoingThis study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…
Phase 1/2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for bile duct cancer patients: expanded access to targeted drug futibatinib
Disease control ApprovedThis program provides futibatinib (TAS-120) to adults with advanced bile duct cancer that has a specific FGFR2 gene change and who have no other treatment options. Participants take one 20 mg pill daily. The goal is to give access to this drug while it is being studied further.
Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC